Experimental Study On Shenhuang Capsule In Prevention And Treatment Of Type2Diabetic Rats With Chronic Complications

Objective:Through the experimental study on shenhuang capsule in prevention and treatment of type2diabetic rats with chronic complications, to evaluate its effectiveness. Methods:SD rats were divided into two groups, one group was control group, fed with normal feed; Another group were the type2diabetic model group, fed with high fat diet for4weeks, then intra peritoneal injection30mg/kg STZ to reproduce the model of type2diabetes mellitus, with fasting blood glucose>7.3mmol/1、2h postprandial blood glucose≥11.1mmol/L, insulin sensitivity index (ISI) is lower than the normal (P<0.05) as success indicators of the models, then the model rats were randomly divided into five groups:shenhuang capsule0.8g/kg,0.4g/kg,0.2g/kg group, metformin0.1g/kg group and model group. Administered group by intra gastric with7.5ml/kg, the control group and the model group were given equal volume of saline, after4weeks of continuous, and then using full automatic blood glucose meter to measure the fasting blood glucose, postprandial2h blood glucose though tail vein blood; And by abdominal blood. Determination blood cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) by automatic blood chemistry analyzer. Determination serum insulin by radioimmunoassay method, ISI=Ln[1/(fasting blood glucose*fasting insulin,) calculate insulin resistance index; determination inflammatory factors, serum C reactive protein (CRP), tumor necrosis factor (TNF-α), interleukin-6(IL-6),advanced glycation end products (AGEs) by enzyme linked immunosorbent assay (ELISA); to measure antioxidant index the serum superoxide dismutase (SOD) though ELISA and malondialdehyde and thiobarbituric acid (MDA) by Thiobarbituric acid method.Determination kidney aldose reductase (AR).Analysis the experimental data using SPSS software. Results:(1)Model replication, model group fasting blood glucose, INS, ISI were17.77±3.04mmol/L,78.4±12.30pg/ml,-7.24±1.15, and compared with the control group4.22±0.69mmol/L,31.52±5.38pg/ml,-4.89±0.11, blood glucose increased, ISI decreased significantly (P<0.01),model group body weight (g), TG (mmol/L), TC (mmol/L) were286±25,4.16±1.17,0.86±0.25, and compared with the control group345±42,1.25±0.14,0.31±0.10, reduction body weight, increased blood lipid (P<0.05);(2)Prevention and treatment T2DM chronic complications related aspects:①Reduce blood glucose:shenhuang capsule high, medium and low dose group, metformin group, model group, control group before meal blood sugar (mmol/L) were10.63±1.91,11.07±2.19,14.07±2.46,9.68±2.09,17.34±2.95,4.32±0.65,2hours postprandial blood glucose (mmol/L) were12.53±2.32,13.48±2.78,16.75±3.11,11.34±1.67,19.26±3.04,6.78±1.23. shenhuang capsule high, medium,low dose group compared with the model group decreased blood glucose significantly (P<0.05), but the effect is less than the metformin group (P<0.05);②lowering lipid: shenhuang capsule high dose group (mmol/1HDL), LDL (mmol/1), TC (mmol/1), TG (mmol/1) were1.11±0.22,0.77±0.40,1.81±0.57,0.50±0.08,0.99±0.53, the medium dose group0.89±0.40,1.96±0.60,0.61±0.19, low dose group0.74±0.17,1.31±0.61,3.04±0.87and0.73±0.23,1.01±0.21metformin group,0.69±0.23,1.74±0.51,0.43±0.12,0.85±0.25in model group,1.51±0.54,4.06±1.13,0.89±0.29,shenhuang capsule high,medium dose group, decreased LDL, TC, TG, increased HDL, with significant difference compared with the model group (P<0.05), equivalent with metformin group (P>0.05);③Ameliorated insulin resistance:shenhuang capsule high dose group INS (pg/ml), ISI were43.55±7.10,-6.14+0.46, the middle dose group47.64±8.93,-6.27±0.49, low dose group53.69±9.68,-6.63±0.78,35.14±6.75metformin group,-5.83±0.44, model group77.4±12.10,-7.2+1.13,shenhuang capsule high, middle dose group can significantly ameliorated IR, there was significant difference compared with model group (P<0.05), and equivalent with metformin group(P>0.05);④Anti-inflammatory effect:shenhuang capsule high dose group CRP (ng/ml), IL-6(pg/ml), TNF-a (pg/ml) were137.87±13.50,44.64±4.07,73.18±10.39,150.37±14.59,the middle dose group48.61±4.53,81.69±8.08, low dose group174.83±25.22,61.11±7.60, 100.84±12.94, metformin group149.28±21.36,44.05±4.62,76.90±9.61,221.02±42.21, model group,78.75±15.85,140.47±37.84, ginseng capsule three doses group can reduce CRP, IL-6, TNF-a, there was significant difference compared with model group (P<0.05), high and middle dose group equivalent with metformin group (P>0.05);⑤Antopxidation: shenhuang capsule high dose SOD (u/ml), MDA (mmol/1) were72.90±8.82,13.85±3.78, middle dose group60.04±4.67,15.42±3.45, low dose group56.83±5.18,19.31±4.03, metformin group,70.72±10.69,14.55±3.72, model group,54.47±6.68,24.67±4.56,Shenhuang capsule high, middle dose group decreased MDA, increased SOD, there was significant difference compared with model group (P<0.05), equivalent with metformin group (P>0.05);⑥Inhibition of AGES, AR:shenhuang capsule high dose group AGES (pg/ml), AR (u/1) were140.59±11.25,3.78±0.28, middle dose group152±14.14,4.05±0.40, low dose group186.24±20.91,4.94±0.29, metformin group152.54±21.17,3.86±0.48, model group204.17±26.29,5.94±0.62,Shenhuang capsule high, middle dose group decreased AGES, AR, there was significant difference compared with model group (P<0.05), equivalent with metformin group (P>0.05).Conclusion:(1) High-fat diet combined with low dose STZ intra peritoneal injection to induce replication the type2diabetes rat model is successful.(2)shenhuang capsule by reducing glycemic, lowering lipid, ameliorating insulin resistance, anti-inflammatory, antioxidant, reducing AGES and AR pathway to prevent and treat type2diabetes rats with chronic complications, high, middle dose group of shenhuang capsule has the same effects with metformin.